Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen's 'modality' play in Tularik

Over the past few years, Amgen Inc.'s R&D efforts have been weighted toward the D side. The investment has paid off, as AMGN has received FDA approval for three new drugs since the second half of 2001. As Aranesp, Neulasta and Kineret moved to market, it was becoming clear that AMGN's research needed to be stepped up. The company had already made clear that

Read the full 642 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE